Development of a long-acting ghrelin derivative as a novel ALS therapeutic

The Defense Health Agency awarded Extend Biosciences Inc. $839,497 on September 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop a long-acting ghrelin derivative as a novel therapeutic for amyotrophic lateral sclerosis (ALS).

Extend Biosciences, a clinical-stage biotechnology company based in Newtonville, Massachusetts, will apply its proprietary D VITylation platform technology—which enhances the pharmacokinetic properties of peptides and proteins—to advance the ghrelin derivative through preclinical and early clinical development. The performance period extends from the award date through September 14, 2027, with work conducted in Newtonville, MA 02458.

The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform health care for Service Members and the American public through innovative solutions for battlefield and military-relevant medical challenges. The program operates through multiple congressionally-directed sub-programs with award cycles throughout the year, typical award periods of three to four years, and amounts ranging from $100,000 to $20 million for consortia, depending on funding priorities and project scope.